Ito K, Sasano H, Yabuki N, Matsunaga G, Sato S, Kikuchi A, Yajima A, Nagura H
Department of Obstetrics and Gynecology, Tohoku University School of Medicine, Sendai, Japan.
Mod Pathol. 1997 Apr;10(4):289-94.
Topoisomerase II (topo II) separates the chromosomes at the end of mitosis, and its expression is limited mostly to the S-to-G2/M phases of the normal cell cycle. We examined the expression of topo II immunohistochemically in 56 specimens of the human endometrium that were retrieved from surgical pathology files. Specimens included proliferative phase mucosa (n = 7), secretory phase mucosa (n = 5), nonatypical adenomatous hyperplasia (n = 7), atypical adenomatous hyperplasia (n = 7) and endometrioid adenocarcinoma (n = 30). We calculated the labeling index (LI) for topo II and correlated the findings with the LI for Ki-67. A significant positive correlation was obtained between the Ki-67 and topo II LIs in all of the specimens examined. The levels of the topo II and Ki-67 LIs in secretory phase endometrium were each significantly lower than in the other cases examined. The levels of the topo II and Ki-67 LIs in adenocarcinoma were significantly higher than those in proliferative phase endometrium and nonatypical hyperplasia. There were no significant differences between atypical hyperplasia and adenocarcinoma in the Ki-67 and topo II LIs. The level of the topo II LI in atypical hyperplasia was significantly higher than that in nonatypical hyperplasia, whereas the Ki-67 LI did not differ between atypical and nonatypical hyperplasia. The levels of the Ki-67 LI were significantly higher than those of the topo II LI in proliferative phase endometrium and in nonatypical hyperplasia, but no significant differences were observed between the LIs in atypical hyperplasia and adenocarcinoma. Topo II immunostaining can identify proliferative cells in routinely processed surgical pathology specimens of human endometrium. The relative overexpression of topo II as compared with Ki-67 in adenocarcinoma suggests a dysregulation or qualitative alteration in topo II associated with malignancy, as reported in other tissues. Such over-expression in atypical hyperplasia might reflect the possible premalignant nature of this type of endometrial hyperplasia.
拓扑异构酶II(topo II)在有丝分裂末期分离染色体,其表达主要局限于正常细胞周期的S期至G2/M期。我们采用免疫组织化学方法检测了从外科病理档案中获取的56例人子宫内膜标本中topo II的表达情况。标本包括增殖期黏膜(n = 7)、分泌期黏膜(n = 5)、非典型腺瘤性增生(n = 7)、非典型腺瘤性增生(n = 7)和子宫内膜样腺癌(n = 30)。我们计算了topo II的标记指数(LI),并将结果与Ki-67的LI进行关联。在所检查的所有标本中,Ki-67和topo II的LI之间存在显著的正相关。分泌期子宫内膜中topo II和Ki-67的LI水平均显著低于其他所检查病例。腺癌中topo II和Ki-67的LI水平显著高于增殖期子宫内膜和非典型增生。非典型增生和腺癌在Ki-67和topo II的LI方面无显著差异。非典型增生中topo II的LI水平显著高于非非典型增生,而非典型增生和非非典型增生之间的Ki-67 LI无差异。增殖期子宫内膜和非典型增生中Ki-67的LI水平显著高于topo II的LI水平,但非典型增生和腺癌的LI之间未观察到显著差异。Topo II免疫染色可在人子宫内膜常规处理的外科病理标本中识别增殖细胞。与其他组织报道的情况一样,腺癌中topo II相对于Ki-67的相对过表达提示与恶性肿瘤相关的topo II失调或质量改变。这种在非典型增生中的过表达可能反映了这种类型子宫内膜增生的可能癌前性质。